Vyant Bio, Inc. Stock Price, News & Analysis

Vyant Bio has appointed Robert Fremeau, Jr., PhD as Chief Scientific Officer to lead R&D initiatives targeting novel therapeutics. The company has entered into two first-phase feasibility programs with biopharma partners and has completed a large AI-generated compound screening for Rett Syndrome, resulting in promising outcomes. A collaboration with Cyclica aims to develop treatments for CDKL5 Deficiency Disorder. As of September 30, 2021, Vyant Bio reported a cash position of $23.2 million, with total revenues of $1.5 million in Q3 2021. The company will file its quarterly report soon.

Vyant Bio, a drug discovery company focused on CNS and oncology diseases, will present at the Q4 Investor Summit Micro & Small Cap Conference on November 17, 2021, from 11:45 AM to 12:15 PM ET. CEO Jay Roberts will discuss recent achievements, including the appointment of a new Chief Scientific Officer and updates on drug discovery programs. The presentation will be webcast live, with an archived recording available for 90 days. Interested investors can register for the event or schedule one-on-one meetings with the company.

Vyant Bio (Nasdaq: VYNT) is set to host an investor conference call and webcast on November 11, 2021, at 4:30 PM ET. The call will feature CEO Jay Roberts and CFO Andy LaFrence, who will discuss Q3 2021 corporate, scientific, financial, and operational results. Investors can participate through details available on the Vyant Bio website. The company focuses on developing therapeutics for central nervous system and oncology diseases, utilizing advanced technologies in drug discovery.

Vyant Bio (Nasdaq: VYNT) has appointed Dr. Robert T. Fremeau Jr. as Chief Scientific Officer, bolstering its drug discovery initiatives in neurology and oncology. Dr. Fremeau has over 20 years of experience in drug development, having held significant roles at Amgen and in academia. His leadership is expected to enhance Vyant Bio's preclinical strategies and drive therapeutic advancements. The company aims to file two investigational new drug applications annually while focusing on reducing drug failure rates through innovative methodologies.

Vyant Bio (Nasdaq: VYNT) has partnered with MASORI Therapeutics to co-develop drug discovery solutions focused on CNS and oncology diseases. The collaboration aims to leverage MASORI's expertise and advanced technology to facilitate partnerships in Japan, enhancing the drug development pipeline. Both companies are committed to innovation, accelerating therapeutic discovery through artificial intelligence and human-derived biology. This agreement could significantly impact Vyant Bio's drug development efforts and market presence.

Vyant Bio (Nasdaq: VYNT), a global drug discovery firm, will present at the H.C. Wainwright 23rd Annual Global Conference from September 13-15, 2021. CEO Jay Roberts will showcase the company's recent merger, partnerships, and future strategies during the virtual event. On-demand access begins at 7:00 a.m. ET on September 13 and ends at 7:00 p.m. ET on September 15. Interested institutional investors can register for the event and schedule one-on-one meetings via the provided link.

Vyant Bio (Nasdaq: VYNT) and Cyclica have announced a strategic collaboration aimed at developing new treatments for CDKL5 Deficiency Disorder (CDD), a severe neurological condition with no current effective treatments. This partnership combines Vyant's patient-derived organoid biology with Cyclica's AI-driven drug discovery platform, facilitating the identification and validation of new drug targets. The collaboration is expected to enhance the efficiency of drug discovery processes, potentially leading to effective therapies for CDD, which affects approximately 1 in 40,000–60,000 live births.

Vyant Bio has achieved significant growth with the issuance of a US Patent for drug discovery technology and a collaboration with Ordaōs Bio and Cellaria, Inc. This partnership aims to enhance therapeutic design using AI and in vitro clinical trials, focusing on oncology. The company completed a primary screening of AI-generated compounds for Rett Syndrome and advanced its toxicology screening for bladder instillation models. As of June 30, 2021, Vyant Bio's cash position was $26.5 million, and it reported revenues of $1.9 million for Q2 2021, a 26% increase pro forma from the previous year.

Vyant Bio, Inc. (Nasdaq: VYNT), a global drug discovery company, is set to host an investor conference call on August 16, 2021. The call will be led by CEO Jay Roberts and CFO Andy LaFrence, highlighting key corporate and scientific milestones from Q2 2021, along with future financial strategies. Vyant Bio specializes in identifying therapeutics for CNS and oncology diseases using advanced research methods, including human cell-derived models. For more details, please visit the Investor section on their website.